# A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis

> **NCT02038049** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 8 (actual)

## Conditions studied

- Relapse Remitting Multiple Sclerosis

## Interventions

- **DRUG:** VAY736
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02038049
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-12-20
- **Primary completion:** 2015-05-05
- **Final completion:** 2018-09-13
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** The study recruitment was terminated based on strategic considerations after 8 patients were enrolled.
- **Last updated:** 2021-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02038049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02038049, "A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT02038049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*